SUMO1 promotes the proliferation and invasion of non‐small cell lung cancer cells by regulating NF‐κB

Abstract

BackgroundOur previous study showed that SUMO1 expression is closely related to progression in non‐small cell lung cancer (NSCLC); however, the function of SUMO1 in NSCLC has not yet been well elucidated.Methods SUMO1 was enhanced or silenced in two NSCLC cell lines by using either forced SUMO1 expression or short hairpin RNA against SUMO1 lentiviral vectors, respectively. The biological functions of SUMO1 in NSCLC were investigated through colony‐formation, cell proliferation, and invasion assays, and cell cycle analysis. NF‐κB expression was detected in the overexpressed and silenced SUMO1 cell lines. Immunohistochemistry was used to detect an association between SUMO1 and NF‐κB in the cancer and adjacent tissues of 168 patients with lung cancer.ResultsOverexpressed SUMO1 promoted the proliferation rate, colony formation ability, invasion, and NF‐κB expression in an A549 cell line. Conversely, SUMO1 depletion inhibited the cell growth rate, colony formation ability, invasion, and NF‐κB expression in a Calu‐1 cell line. SUMO1 expression was significantly correlated with NF‐κB expression in lung adenocarcinoma and squamous carcinoma patients (r > 0.5, P < 0.001).ConclusionOur results provide evidence that SUMO1 promotes the proliferation and invasion of NSCLC cells by regulating NF‐κB.

Resveratrol Attenuates Inflammatory Bowel Disease in Mice by Regulating SUMO1

“…SUMO1 is a member of the SUMO gene family and its modification regulates many protein functions such as P53, proliferating cell nuclear antigen (PCNA) and telomerase. [9][10][11] In addition, SUMO1 is also involved in the regulation of signaling pathways such as nuclear factor-kappaB (NF-κB), Wnt/β-catenin, transforming growth factor-β (TGF-β) and c-Jun N-terminal kinase (JNK). 12,13) Based on the characteristics of SUMO1, it plays an important role in many diseases such as inflammation-related diseases, tumors, and kidney diseases.…”

“…[9][10][11] In addition, SUMO1 is also involved in the regulation of signaling pathways such as nuclear factor-kappaB (NF-κB), Wnt/β-catenin, transforming growth factor-β (TGF-β) and c-Jun N-terminal kinase (JNK). 12,13) Based on the characteristics of SUMO1, it plays an important role in many diseases such as inflammation-related diseases, tumors, and kidney diseases. [14][15][16] In our study, we researched the role of resveratrol in inhibiting the expression of SUMO1 and the Wnt/β-catenin pathway in dextran sodium sulfate (DSS)-induced IBD.…”

Expression of SUMO1P3 Compared with SUMO1 is an Independent Predictor of Patient Outcome in Lung Adenocarcinoma

“…Recurrence-free survival (RFS) was defined as the survival time from the date of primary surgery to the time of locoregional or distant recurrence of lung cancer. Although the upregulation of SUMO1 in lung cancer has previously been reported [14], the expression profile of its pseudogene SUMO1P3 has not been characterized. Using RNA-Seq data from around 500 tumor samples, we compared the expression of SUMO1P3 in both LUSC and LUAD.…”

“…Pseudogenes can be functionally linked with protein-coding genes [12,13]. A recent study showed that the small ubiquitin-like modifier 1 ( SUMO1 ) gene mediated a post-translational modification process called SUMOylation, which was also upregulated in NSCLC [14]. SUMO1 dysregulation might be associated with chemosensitivity of NSCLC cells [15].…”

“…SUMO1 dysregulation might be associated with chemosensitivity of NSCLC cells [15]. Also, SUMO1 overexpression can promote changes in the cell cycle and the progression and invasion of NSCLC cells by enhancing NF-κB expression [14]. However, the expression profiles of SUMO1P3 and the prognostic value of SUMO1P3 and SUMO1 in NSCLC remain to be characterized.…”